# of Displayed Technologies: 2 / 2


Categories

Compound 13, an Mps1/TTK Kinase Inhibitor, for Triple Negative Breast Cancer Therapy
TS-037724 — Researchers at The Ohio State University have discovered Compound 13, a patent protected, orally bioavailable and brain penetrant Mps1/TTK inhibitor that exhibits single agent tumor growth inhibition in a murine xenograft model of human triple negative breast cancer upon daily administration.
Breast cancer is a heterogeneous group of tumors, which can be subdivided based on histopathological features, genetic alterations, and gene-expression profiles. Approximately 50-60% of all breast cancer patients and two-thirds of postmenopausal breast cancer patients have estrogen receptor positi…
  • College: College of Pharmacy
  • Inventors: Brueggemeier, Robert; Fisk, Harold; Li, Chenglong; Li, Pui-Kai "Tom"; Sugimoto, Yasuro
  • Licensing Officer: Davis, Stewart

Development of STAT3 dimerization inhibitors for cancers
TS-037569 — The constant activation of Signal Transducer and Activator of Transcription 3 (STAT3) is frequently detected in many cancer patients with advanced diseases. About 80% of all cancers overexpress STAT3, including solid tumors, lymphoma, and leukemia. Constant activation of STAT3 activities in nonmal…
  • College: College of Pharmacy
  • Inventors: Li, Pui-Kai "Tom"; Li, Chenglong; Lin, Jiayuh
  • Licensing Officer: Ezzell, Janel

Loading icon